Biotech · Private company · San Diego, CA, US
Mapp Biopharmaceutical, Inc.
Track this companyFree. Adds Mapp Biopharmaceutical, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards3
- Development of highly potent human monoclonal for RSV immunoprophylaxisFiscal year 2026 · $993.4KNIH RePORTER 5SB1AI191871-02 · fetched Nov 12, 2026
- A Novel Cost-Effective Multispecific Therapeutic for DengueFiscal year 2025 · $294.6KNIH RePORTER 1R44AI192180-01 · fetched Nov 12, 2026
- Development of highly potent human monoclonal for RSV immunoprophylaxisFiscal year 2025 · $993.4KNIH RePORTER 1SB1AI191871-01A1 · fetched Nov 12, 2026